Gala vs Lttl
Gala and Lttl both sell semaglutide and tirzepatide; this is how their prices, coverage and records differ.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
If you are choosing between Gala and Lttl, price alone will not settle it. Both prescribe semaglutide and tirzepatide, so moving from one to the other would not change your drug. Gala leads our six-part score, 8.7 to 8.0.
Gala vs Lttl price
Gala and Lttl start at the same figure, $149 a month, so the entry price does not separate them. Look at what each price covers and at the per-drug prices below.
Drug by drug: Semaglutide is cheaper at Lttl ($149 a month vs $179 a month); tirzepatide costs the same at both, $149 a month.
Medications and formats
Both sell semaglutide and tirzepatide.
On format, Gala prices compounded injections and brand-name pens, while Lttl prices compounded injections.
If you want the FDA-approved brand rather than a compounded version, Gala is the only one of the two with a brand-name price.
Where each one treats patients
Gala lists 50 states, and Lttl does not publish where it ships.
Pricing
Gala
$179/mo on a yearly subscription, all doses included. Gala's FAQ says 'starting at just $199 per month (with a 3-month plan).' A promo page offers 'starting at $129/month with $120 off your first shipment' on monthly, 3-, 6- and 12-month plans. Exact plan prices appear only after the intake questionnaire.
$179/month on a yearly subscription, all doses included; the $120-off-first-shipment promo applies. Tirzepatide plan prices are shown only after intake.
$149/month, yearly subscription; 'Low-dose GLP-1/GIP for sustained energy, sleep and metabolic balance.'
'Ozempic® Brand-name semaglutide $1,299/month' — unchanged. Wegovy pill still 'Coming soon / Pricing at launch' (not a priced row).
Lttl
Month-to-month 'Monthly Auto-Refill' rate, was $249. Commitment ladder published on /plans: $169/mo billed $507 quarterly, $149/mo billed $894 every 6mo, $129/mo billed $1,548 annually. Promo is a one-time 'First Month Special' at $149 ('$149 - first month only'). The homepage 'Plans start at $129/mo' headline is the 12-month prepay rate.
Month-to-month rate, was $339. Ladder: $249/mo billed $747 quarterly, $229/mo billed $1,374 every 6mo, $199/mo billed $2,388 annually. One-time First Month Special $199. The '$199 per month' figure advertised on /weight-loss is the 12-month prepay rate.
Needle-free oral option. Month-to-month, was $279. Ladder: $199 quarterly, $179 every 6mo, $159 annually. First Month Special $179.
Low-dose line marketed for tolerability. Month-to-month, was $179. Ladder: $129 quarterly, $119 every 6mo, $109 annually. First Month Special $119.
Low-dose GLP-1 + GIP. Same ladder as microdose semaglutide: $129 quarterly, $119 every 6mo, $109 annually. First Month Special $119.
Month-to-month, was $209. Ladder: $159 quarterly, $149 every 6mo, $139 annually. First Month Special $149.
What each price covers
Both prices cover the clinician visit, the medication itself and shipping.
Gala is silent on lab work and coaching.
Lttl is silent on lab work and coaching.
Gala
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Lttl
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Where each one scores higher
Overall, Gala scores 8.7 and Lttl 8.0 out of 10.
Gala is stronger on trust & safety (7.5 vs 6.5) and accessibility (10.0 vs 5.0).
Value, effectiveness, user experience and support are within half a point.
Gala
8.7/10
Lttl
8.0/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
FDA warning letters
Neither Gala nor Lttl has an FDA warning letter on record with us.
Features & Coverage
| Feature | Gala | Lttl |
|---|---|---|
| Starting Price | $149/mo | $149/mo |
| Features | 7 features | ✓8 features |
| States Available | 50 | Not disclosed |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | ✓ Yes |
| FDA Warning Letters | None | None |
About Gala
A yearly subscription is the format: compounded semaglutide and compounded tirzepatide are sold that way, with a cheaper microdosing program beside them and brand-name Ozempic on the same menu. The corporate name is AI Coaching Inc., which does business as Gala GLP-1 and is incorporated in Delaware. Providers licensed in every one of the 50 states, plus shipping at no cost, are what the marketing site claims. A Wegovy pill taken orally is flagged as coming soon.
Read our full Gala review →About Lttl
Prepay for 12 months and compounded semaglutide drops to $129 with tirzepatide at $199; taken month to month they run $199/mo and $279/mo, one flat rate at any dose. Before checkout the entire price matrix is on view, every commitment length, form and medication in it. Longevity peptides and a microdose line at low dose fill out the direct-to-consumer catalog. The name is said aloud as little.
Read our full Lttl review →Pros & Cons
Gala
What we like
- Semaglutide costs $179 a month, close to the $184 median for compounded semaglutide across the sellers we compare
- Tirzepatide costs $149 a month, 40% below the $250 median for compounded tirzepatide across the sellers we compare
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price stays the same as your dose goes up
- The monthly price includes the medication, clinician visits and shipping
- Serves all 50 states
- We found no FDA warning letters issued to Gala
Watch-outs
- Ask which pharmacy fills the prescription before you pay, so you can check its license
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Lttl
What we like
- Semaglutide costs $149 a month, 19% below the $184 median for compounded semaglutide across the sellers we compare
- Tirzepatide costs $149 a month, 40% below the $250 median for compounded tirzepatide across the sellers we compare
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price stays the same as your dose goes up
- The monthly price includes the medication, clinician visits and shipping
- We found no FDA warning letters issued to Lttl
Watch-outs
- Confirm it serves your state before you start the intake
- Ask which pharmacy fills the prescription before you pay, so you can check its license
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Our Verdict
Gala wins this one, 8.7 to 8.0, above all for moving between compounded and brand without changing seller. Lttl fits better if starting below a standard dose, with microdose tiers is your priority.
Choose Gala if…
You want moving between compounded and brand without changing seller and an opening price near $149 a month.
Choose Lttl if…
You want starting below a standard dose, with microdose tiers and an opening price near $149 a month.
Ready to start? GLP-1 providers we have vetted
Telehealth providers, vetted by us, prescribing GLP-1 online.
Vetted by our editors · no insurance required
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Breeze Meds
Knowing which pharmacy fills the vial: it names Belmar Pharmacy
From $199/mo
Get started →HealthRX
Compounded semaglutide at $133/month
From $133/mo
Get started →RNK Health
An oral route if you will not self-inject
From $197/mo
Get started →Gala vs Lttl: FAQ
Close alternatives to Gala and Lttl
- Gala vs altRX
- Gala vs Sprout Health
- Gala vs Aquivia Health
- Gala vs Vytora Health
- Lttl vs altRX
- Lttl vs Trinity Meds
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.